US · TXG
10x Genomics, Inc.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Pleasanton, CA 94588-3260
- Website
- 10xgenomics.com
Price · as of 2025-12-31
$22.43
Market cap 2.94B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $55.63 | +148.02% |
| Intrinsic Value(DCF) | $10.31 | -54.03% |
| Graham-Dodd Method(GD) | $4.60 | -79.48% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $71.28 | $113.04 | $8,641.98 | $6.75 | $0.00 |
| 2020 | $160.02 | $155.62 | $334.78 | $0.00 | $0.00 |
| 2021 | $61.67 | $62.95 | $1,200.18 | $4.73 | $0.00 |
| 2022 | $45.00 | $37.32 | $23.98 | $0.00 | $0.00 |
| 2023 | $39.81 | $37.98 | $21.55 | $0.00 | $0.00 |
| 2024 | $11.70 | $32.00 | $0.00 | $0.00 | $0.00 |
| 2025 | $23.14 | $55.63 | $1.69 | $4.60 | $0.00 |
AI valuation
Our deep-learning model estimates 10x Genomics, Inc.'s (TXG) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $55.63
- Current price
- $22.43
- AI upside
- +148.02%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$10.31
-54.03% upside
Graham-Dodd
$4.60
-79.48% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TXG | 10x Genomics, Inc. | $22.43 | 2.94B | +148% | -54% | -79% | — | -66.29 | 3.63 | 4.49 | -22.74 | — | 3.96 | 69.05% | -17.25% | -6.77% | -5.78% | -26.72% | -4.44% | 0.20 | — | 4.46 | 3.95 | 2.85 | -7697.00% | 525.00% | -237116.00% | 4.51% | 0.89 | 31.35% | 0.00% | 0.00% | 1.90% | -22.74 | 19.38 | 3.92 | 5.92 |
| CERT | Certara, Inc. | $7.08 | 1.13B | +312% | -51% | -75% | — | -708.95 | 1.06 | 2.70 | 11.35 | — | -7.16 | 61.53% | 5.02% | -0.38% | -0.15% | 0.81% | -0.10% | 0.01 | 1.06 | 2.05 | 1.91 | -2.12 | -8668.00% | 875.00% | 1994.00% | 8.36% | 0.63 | 9.11% | 0.00% | 0.00% | 31.25% | 45.34 | 10.08 | 2.27 | 1.70 |
| GRDN | Guardian Pharmacy Service… | $33.51 | 2.12B | -11% | +240% | — | — | -16.12 | 8.03 | 0.93 | -27.12 | — | 19.59 | 19.89% | -5.12% | -7.11% | -83.14% | -46.27% | -24.00% | 0.26 | -19.19 | 1.05 | 0.71 | -0.75 | -55385.00% | 1742.00% | -2608.00% | 3.63% | 0.40 | 30.59% | 3.12% | -50.30% | 11.06% | -18.72 | 28.32 | 0.96 | 7.31 |
| JANX | Janux Therapeutics, Inc. | $13.61 | 818.61M | +171% | -7% | -80% | — | — | 0.87 | 83.16 | 0.99 | — | 0.87 | 79.71% | -1576.67% | -1576.67% | 0.00% | -954.78% | 0.00% | 0.02 | — | 39.04 | 38.67 | 0.27 | 4297.00% | -555.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 0.00% | 0.72 | — | -11.28 | 11.29 |
| NUVB | Nuvation Bio Inc. | $5.91 | 2.02B | — | — | — | — | -0.96 | 1.17 | 68.96 | -0.09 | -0.19 | 1.18 | 10.10% | -7527.33% | -7213.76% | -106.27% | 3695.49% | -97.74% | 0.02 | -1737.91 | 9.04 | 8.91 | 0.05 | 50286.00% | — | 9183.00% | -24.05% | -2.24 | 814.24% | 0.00% | 0.00% | 0.00% | -0.08 | -0.38 | 6.24 | -0.68 |
| OMCL | Omnicell, Inc. | $41.10 | 1.89B | +33% | -57% | -73% | -98% | 924.00 | 1.54 | 1.60 | 19.91 | — | 5.86 | 42.49% | 0.44% | 0.17% | 0.17% | 0.17% | 0.10% | 0.18 | 0.84 | 1.43 | 0.87 | 0.21 | -8359.00% | 653.00% | -4256.00% | 4.58% | 0.27 | 6.96% | 0.00% | 0.00% | 4.09% | 371.46 | 22.06 | 1.62 | 2.26 |
| OMDA | Omada Health | $12.28 | 711.11M | — | — | — | — | — | — | — | — | — | — | 60.59% | -25.71% | -27.76% | -57.64% | -270.44% | -28.92% | 0.47 | -9.69 | 2.10 | 1.86 | 1.22 | -2975.00% | 3829.00% | -2776.00% | — | -0.63 | -235.67% | — | 0.00% | — | — | — | — | — |
| PGNY | Progyny, Inc. | $17.69 | 1.53B | +175% | +6% | -48% | -30% | 25.63 | 2.91 | 1.16 | 12.09 | 182.64 | 3.06 | 23.63% | 6.62% | 4.54% | 12.48% | 23.59% | 8.67% | 0.05 | — | 2.73 | 2.62 | -0.88 | 1404.00% | 1040.00% | 1041.00% | 12.78% | 1.04 | 86.52% | 0.00% | 0.00% | 5.44% | 14.24 | 6.33 | 0.94 | 6.66 |
| SDGR | Schrödinger, Inc. | $12.06 | 888.4M | +184% | -53% | — | — | -8.64 | 2.45 | 3.49 | -6.29 | — | 2.48 | 55.74% | -65.23% | -40.36% | -26.29% | -125.97% | -13.33% | 0.30 | — | 2.75 | 2.53 | 1.26 | -4514.00% | 2329.00% | -10756.00% | 1.40% | 0.07 | 9.40% | 0.00% | 0.00% | 10.29% | -3.63 | 48.66 | 2.37 | 0.41 |
| SION | Sionna Therapeutics, Inc. | $36.54 | 1.63B | — | — | — | — | -11.64 | -4.39 | — | -8.30 | -37.90 | -4.39 | 0.00% | — | — | 44.29% | 31.75% | -51.90% | -0.06 | — | 14.49 | 14.16 | 0.40 | 3071.00% | — | 1785.00% | -7.36% | -5.07 | 23.77% | 0.00% | 0.00% | 0.00% | -8.22 | -10.98 | — | -0.48 |
| TDOC | Teladoc Health, Inc. | $5.26 | 933.51M | +398% | -42% | -89% | — | -4.54 | 0.66 | 0.36 | 7.86 | — | -4.67 | 69.50% | -10.39% | -7.92% | -13.93% | -13.11% | -6.28% | 0.74 | -13.34 | 2.77 | 2.41 | 1.68 | -8058.00% | -154.00% | 91.00% | 31.39% | 0.73 | 16.74% | 0.00% | 0.00% | 4.21% | -4.40 | 4.05 | 0.46 | -6.80 |
About 10x Genomics, Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
- CEO
- Serge Saxonov
- Employees
- 1.31K
- Beta
- 2.24
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($10.31 ÷ $22.43) − 1 = -54.03% (DCF, example).